Litigation Details for ACTELION PHARMACEUTICALS LTD. v. KAPPOS (D.D.C. 2010)

ACTELION PHARMACEUTICALS LTD. v. KAPPOS (D.D.C. 2010)

Docket		Date Filed	2010-07-06
Court	District Court, District of Columbia	Date Terminated	2013-09-24
Cause	35:145 Patent Infringement	Assigned To	Richard J. Leon
Jury Demand	None	Referred To
Parties	ACTELION PHARMACEUTICALS LTD.
Patents	7,094,781
Attorneys	Thomas Hoxie
Firms	Hoxie & Associates, LLC
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD. v. KAPPOS (D.D.C. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-07-06				External link to document

Actelion Pharmaceuticals Ltd. v. Kappos, 1:10-cv-01145: Litigation Summary and Patent-Term Analysis

Last updated: August 9, 2026

Actelion Pharmaceuticals Ltd. v. Kappos was a U.S. District Court for the District of Columbia action concerning the U.S. Patent and Trademark Office’s calculation of patent term adjustment under 35 U.S.C. § 154(b). The case was an administrative patent-term dispute, not a Hatch-Waxman infringement action. It did not involve a Paragraph IV certification, generic defendant, Orange Book validity challenge, or biosimilar proceeding.

The dispute arose from the USPTO’s treatment of overlapping statutory patent-term delays, particularly the interaction between USPTO examination delays and the statutory three-year examination period. The litigation was part of the broader wave of patent-term-adjustment cases that followed the Federal Circuit’s decision in Wyeth v. Kappos.

What was the legal issue in Actelion Pharmaceuticals v. Kappos?

The core issue was whether the USPTO had correctly calculated Actelion’s patent term adjustment under 35 U.S.C. § 154(b).

Patent term adjustment compensates an applicant for specified USPTO delays during prosecution. The statute contains several principal categories:

PTA category	Statutory basis	General description
“A” delay	35 U.S.C. § 154(b)(1)(A)	Failure to meet specified examination and response deadlines
“B” delay	35 U.S.C. § 154(b)(1)(B)	Failure to issue a patent within three years after filing
“C” delay	35 U.S.C. § 154(b)(1)(C)	Delays caused by appeal, secrecy orders, or interference proceedings
Applicant delay	35 U.S.C. § 154(b)(2)(C)	Time attributable to the applicant’s failure to engage in reasonable efforts

The principal legal question was whether the USPTO could reduce the statutory adjustment by treating overlapping categories of USPTO delay as mutually exclusive when calculating the final patent term.

The district court applied the Federal Circuit’s reasoning in Wyeth, which rejected the USPTO’s earlier interpretation that “A” and “B” delays could be calculated in a manner that eliminated overlapping periods without statutory support. The governing principle was that the applicant receives the greater of the applicable A-delay or B-delay periods, subject to statutory overlap and applicant-delay limitations. Wyeth v. Kappos, 591 F.3d 1364, 1370-73 (Fed. Cir. 2010).

When was the Actelion patent-term case filed and decided?

The case was filed in 2010 in the U.S. District Court for the District of Columbia under Case No. 1:10-cv-01145. The defendant was David Kappos, then Director of the USPTO.

The reported district-court decision issued in December 2011. The action proceeded under the Administrative Procedure Act and related patent-term provisions. The court reviewed the USPTO’s administrative calculation rather than conducting a conventional patent-infringement or patent-validity trial. Actelion Pharmaceuticals Ltd. v. Kappos, No. 1:10-cv-01145, 2011 WL 6934557 (D.D.C. Dec. 30, 2011).

Key procedural milestones

Date	Event
2010	Actelion filed the district-court action against USPTO Director David Kappos
2010-2011	The parties briefed the statutory calculation of patent term adjustment
December 2011	The district court issued its reported decision
Post-decision	The case remained part of the broader PTA litigation landscape shaped by Wyeth

The case was decided on the administrative record and statutory interpretation. There is no indication that the litigation produced a damages award, injunction, infringement finding, or generic-launch judgment.

What did the court decide about patent term adjustment?

The court treated the USPTO’s PTA calculation as subject to judicial review and applied the statutory framework as interpreted in Wyeth. The significance of the ruling was that the USPTO could not rely on an overly restrictive calculation methodology to reduce the applicant’s statutory adjustment.

The decision belongs to the group of cases requiring the USPTO to recalculate patent terms where the agency had applied its pre-Wyeth approach to overlapping A and B delays. The result was a correction or reconsideration of the patent term rather than a ruling on the underlying patent’s validity or enforceability.

The legal effect was narrow:

1. The case addressed the duration of patent protection.
2. It did not determine whether the patent claims were valid.
3. It did not determine whether a third party infringed.
4. It did not establish that Actelion’s commercial product had a particular period of market exclusivity.
5. It did not resolve a Paragraph IV dispute.

The ruling’s commercial relevance depended on the additional term awarded to the patent at issue. A PTA ruling can extend the enforceable life of a patent beyond the nominal 20-year term measured from the effective nonprovisional filing date, but the precise commercial effect depends on the patent number, expiration calculation, terminal disclaimers, regulatory exclusivity, and the scope of any listed claims.

What patents and products were involved?

The docket concerns Actelion’s patent-term rights, but the litigation was not a product-labeling or Orange Book case. The reported decision is principally cited for patent-term-adjustment methodology rather than for a definitive holding on a particular drug’s formulation, method of use, or active ingredient.

Actelion’s major U.S. products during the relevant period included:

Product	Active ingredient	Therapeutic area	Relevance to this case
Tracleer	Bosentan	Pulmonary arterial hypertension	Actelion commercial product; not the subject of an infringement judgment in this action
Ventavis	Iloprost	Pulmonary arterial hypertension	Commercial product; no direct Hatch-Waxman ruling in this docket
Veletri	Epoprostenol	Pulmonary arterial hypertension	Commercial product; no direct litigation holding in this docket
Zavesca	Miglustat	Gaucher disease and other indications	No direct product litigation holding in this docket

The case should not be cited as authority for the expiration date of any specific Actelion drug patent without reviewing the underlying patent and USPTO recalculation records.

What was the Orange Book status of Actelion v. Kappos?

Actelion v. Kappos was not an Orange Book case.

The defendant was the USPTO Director, not a generic drug manufacturer. The action did not involve:

• An ANDA filing;
• A Paragraph IV certification;
• A 30-month stay;
• An infringement action under 35 U.S.C. § 271(e)(2);
• A generic applicant’s invalidity or noninfringement position;
• A settlement agreement between a branded and generic manufacturer.

The case therefore provides no direct evidence regarding generic entry timing for Tracleer, Ventavis, Veletri, Zavesca, or another Actelion product. Its relevance to generic competition is indirect: a successful PTA challenge can extend the life of a patent that may later be asserted against an ANDA applicant.

Did the case involve formulation or method-of-use patents?

The reported litigation was not a merits challenge to formulation patents or method-of-use patents.

The court did not decide whether Actelion had enforceable protection for:

• A particular bosentan formulation;
• A controlled-release dosage form;
• A pulmonary hypertension treatment regimen;
• A dosing schedule;
• A patient-selection method;
• A manufacturing process;
• A salt, polymorph, or crystalline form.

Those patent categories can be commercially important in pharmaceutical exclusivity analysis, but the Actelion decision is principally relevant to the term of the patent, not the patent’s substantive claim scope.

Formulation-patent implications

A PTA award can extend a formulation patent beyond the expected expiration date if the patent has meaningful remaining claim scope. Its commercial value is lower where:

• The patent is terminally disclaimed;
• The claims are narrow or vulnerable to invalidity;
• A competing product avoids the protected formulation;
• FDA labeling does not require the patented formulation;
• The patent is not listed in the Orange Book;
• The remaining patent term falls after loss of practical market share.

Method-of-use implications

A method-of-use patent may remain relevant after composition or formulation patents expire. In an ANDA setting, the scope of the approved label and the generic applicant’s Paragraph IV or section viii strategy would determine the practical effect. Actelion v. Kappos did not address those issues.

How does Actelion compare with Wyeth v. Kappos?

Issue	Actelion v. Kappos	Wyeth v. Kappos
Court	U.S. District Court for the District of Columbia	U.S. Court of Appeals for the Federal Circuit
Defendant	USPTO Director	USPTO Director
Main issue	Application of PTA principles to Actelion’s patent-term calculation	Scope and interaction of A and B delay
Drug infringement dispute	No	No
Paragraph IV challenge	No	No
Commercial product ruling	No direct ruling	No direct ruling
Broader impact	Applied the post-Wyeth framework to Actelion’s dispute	Established controlling Federal Circuit interpretation

Wyeth was the controlling appellate authority. Actelion was a later district-court application of that framework to an individual applicant’s patent-term dispute.

What was the litigation outcome and business impact?

The litigation produced a patent-term-adjustment determination rather than a conventional infringement judgment. The business impact was the potential restoration of patent term that the USPTO had not credited under its earlier methodology.

The value of the outcome depended on four factors:

1. The number of additional days awarded.
2. The commercial importance of the underlying patent.
3. Whether the patent was listed or listable in the Orange Book.
4. Whether the patent covered the marketed product, an essential formulation, or a required method of use.

The case did not establish a broad Actelion monopoly over pulmonary hypertension therapies. It also did not block competitors, require FDA action, or determine the timing of generic or biosimilar entry.

What generic entry risks existed after the Actelion ruling?

The case created no immediate generic-entry bar because no generic defendant was before the court.

Generic-entry risk would have required a separate analysis of:

• FDA-approved products and reference-listed drugs;
• Orange Book patent listings;
• Patent expiration dates after PTA;
• Terminal disclaimers;
• Paragraph IV certifications;
• ANDA filing dates;
• 30-month litigation stays;
• Section viii carve-outs;
• Pediatric exclusivity;
• New chemical entity exclusivity;
• Any branded-generic settlement.

Biosimilar risk was not relevant. Actelion’s products are small-molecule or non-biologic products for purposes of the principal FDA approval pathway, so the Biologics Price Competition and Innovation Act framework did not govern this case.

How strong was the patent estate after the decision?

The decision strengthened the duration component of Actelion’s patent position but did not establish claim validity or infringement strength.

A practical patent-strength assessment must separate:

Dimension	Effect of Actelion decision
Patent duration	Potentially favorable because PTA could increase the enforceable term
Validity	Not adjudicated
Infringement	Not adjudicated
Orange Book leverage	Not established
Formulation protection	Not adjudicated
Method-of-use protection	Not adjudicated
Manufacturing barriers	Not adjudicated
Geographic coverage	Limited to U.S. patent-term rights
Licensing value	No licensing rights were adjudicated
Generic-launch risk	Not directly resolved

The decision had U.S.-only effect. It did not alter European Patent Office, United Kingdom, Japanese, Canadian, or other national patent terms. PTA under § 154(b) is a U.S. statutory mechanism and does not create international patent-term extensions.

Did Actelion v. Kappos involve a licensing deal or settlement?

The case did not adjudicate a licensing transaction. The reported decision does not establish a license, royalty obligation, co-commercialization arrangement, or branded-generic settlement.

Any commercial agreement involving Actelion, Johnson & Johnson, Janssen, or a generic manufacturer would need to be analyzed separately from this docket. The PTA case itself is not evidence of an authorized generic arrangement or a reverse-payment settlement.

Key Takeaways

• Actelion Pharmaceuticals Ltd. v. Kappos was a patent-term-adjustment case in the District of Columbia.
• The dispute involved USPTO calculation of statutory patent term under 35 U.S.C. § 154(b).
• The case followed the Federal Circuit’s decision in Wyeth v. Kappos.
• It was not a Hatch-Waxman infringement action.
• It involved no Paragraph IV certification, ANDA defendant, Orange Book ruling, or generic settlement.
• The decision concerned patent duration, not validity, infringement, formulation scope, method-of-use scope, or manufacturing rights.
• The commercial value of the ruling depended on the underlying patent and the number of additional PTA days credited.
• The ruling had U.S.-only effect and did not change foreign patent terms.
• Biosimilar risk was not relevant to the litigation.

FAQs About Actelion Pharmaceuticals Ltd. v. Kappos

Was Actelion v. Kappos a patent-infringement case?

No. It was an administrative challenge concerning the USPTO’s calculation of patent term adjustment.

Did Actelion v. Kappos delay generic entry?

Not directly. No generic manufacturer was a party, and the case did not impose an ANDA stay or enter an injunction.

What statute governed the Actelion patent-term dispute?

The principal statute was 35 U.S.C. § 154(b), which governs patent term adjustment for USPTO and applicant delays.

Did the court invalidate any Actelion patent?

No. The court did not issue a patent-validity ruling.

Does Actelion v. Kappos determine the expiration date of Tracleer patents?

No. The case should not be used alone to determine Tracleer’s patent expiration dates. Those dates require patent-specific PTA, terminal-disclaimer, Orange Book, and regulatory-exclusivity analysis.

References

1. Actelion Pharmaceuticals Ltd. v. Kappos, No. 1:10-cv-01145, 2011 WL 6934557 (D.D.C. Dec. 30, 2011).

2. 35 U.S.C. § 154(b) (2024).

3. Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010).

4. U.S. Patent and Trademark Office. (2010). Manual of Patent Examining Procedure § 2730: Patent term adjustment under 35 U.S.C. § 154(b).

5. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Washington, DC: U.S. Department of Health and Human Services.